Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Total Current Liabilities: 2022-2025

Historic Total Current Liabilities for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $1.4 million.

  • Addex Therapeutics' Total Current Liabilities rose 33.26% to $1.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.4 million, marking a year-over-year increase of 33.26%. This contributed to the annual value of $911,740 for FY2024, which is 71.70% down from last year.
  • As of Q2 2025, Addex Therapeutics' Total Current Liabilities stood at $1.4 million, which was up 18.22% from $1.2 million recorded in Q1 2025.
  • Addex Therapeutics' Total Current Liabilities' 5-year high stood at $5.3 million during Q1 2024, with a 5-year trough of $915,607 in Q4 2024.
  • For the 3-year period, Addex Therapeutics' Total Current Liabilities averaged around $2.3 million, with its median value being $1.8 million (2023).
  • As far as peak fluctuations go, Addex Therapeutics' Total Current Liabilities surged by 54.77% in 2024, and later plummeted by 77.96% in 2025.
  • Quarterly analysis of 4 years shows Addex Therapeutics' Total Current Liabilities stood at $3.4 million in 2022, then fell by 4.26% to $3.3 million in 2023, then slumped by 71.93% to $915,607 in 2024, then soared by 33.26% to $1.4 million in 2025.
  • Its Total Current Liabilities was $1.4 million in Q2 2025, compared to $1.2 million in Q1 2025 and $915,607 in Q4 2024.